Pretreatment of a biological sample from an autoimmune disease subject

Patent Citations (144)

Non-Patent Literature (287)

• Christen et al., “Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities” Human Immunology 60(9):774-790 (Sep. 1999).Applicant
• Tincani et al., “The anti-β2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native β2-glycoprotein I and preserved during species' evolution” Journal of Immunology 157(12):5732-5738 (Dec. 15, 1996).Applicant
• Ahn et al., “Long-term remission from life-threatening hypercoaulable state associated with lupus anticoagulant (LA) following rituximab therapy” Am. J. Hematol. 78(2) :127-129 (2005).Applicant
• Ahn et al., “Severe hypercoabulable state and concomitant life threatening bleeding successfully treated with rituximab” Blood (Abstract #4139) 102(11) :108b (Nov. 16, 2003).Applicant
• Akashi et. al., “Successful Treatment of Refractory Systemic Lupus Erythematosus with Intravenous Immunoglobulins” J. Rheumatology 17:375-379 (1990).Applicant
• Albert et al., “A Phase 1 trial of Rituximab (Anti-CD20) for treatment of Systemic Lupus Erythematous” Arthritis Rheum. (Abstract #LB9) 48(12) :3659 (Dec. 2003).Applicant
• Anderson et al., “Expression of Human B Cell-Associated Antigens on Leukemias and Lymphomas: A Model of Human B Cell Differentiation” Blood 63(6) :1424-1433 (1984).Applicant
• Anderson et al., “Revised estimate of the prevalence of multiple sclerosis in the United States” Ann Neurol. 31(3) :333-336 (Mar. 1992).Applicant
• Andersson et al., “Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis” Eur J Neurol. 9(3) :243-251 (May 2002).Applicant
• Andrassy et al., “Wegener's granulomatosis with renal involvment: patient survival and correlations between initial renal function renal histology, therapy and renal outcome” Clinical Nephrology 35:139-147 (1991).Applicant
• Anolik et al., “B cell depletion therapy in systemic lupus erythematosus” Current Rhematology Reports 5(5) :350-356 (Oct. 2003).Applicant
• Anolik et al., “B lymphocyte depletion as a novel treatment for systemic lupus erythematosus (SLE): Phase I/II trial of rituximab (Rituxan (R)) in SLE” Arthritis and Rheumatism (Abstract # 2009) 44(9) ;S387 (Sep. 2001).Applicant
• Anolik et al., “B lymphocyte Depletion in the treatment of Systemic Lupus (SLE): Phase I/II trial of Rituximab (RITUXAN) in SLE” Arthritis and Rheumatism (Abstract #717) 46(9) :S289 (Oct. 2002).Applicant
• Anolik et al., “The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus” Arthritis and Rheumatism 48 (2) :455-459 (Feb. 2003).Applicant
• Arbuckle et al., “Development of autoantibodies before the clinical onset fo systemic lupus erythematosus” New England J. of Medicine 349(16):1526-1533 (Oct. 16, 2003).Applicant
• Arzoo et al., “Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)” Annals of the Rheumatic Diseases 61(10):922-924.Applicant
• Auner et al., “Restoration of erythropoiesis by rituximab in an adult patient with primary acruired pure red cell aplasia refractory to conventional treatment” Br J Haematol. 116(3):727-728 (Mar. 2002).Applicant
• Baker et al., “Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator” Arthritis and Rheumatism 48(11) :3253-3256 (Nov. 2003).Applicant
• Balow et al., “Vasculitic diseases of the kidney, polyarteritis, Wegener's granulomatosis, necrotizing and crescentic glomerulonephritis, and other disorders” Diseases of the Kidney, Schrier and Gottschalk, 5th edition, Boston:Little, Brown and Compan pp. 2095-2117 (1993).Applicant
• Bauduer, “Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma” Br J Haematol. 112(4) :1085-1086 (Mar. 2001).Applicant
• Berentsen et al., “Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in promary chronic cold agglutinin disease” Br J Haemetol. 115(1) :79-83 (Oct. 2001).Applicant
• Berentsen et al., “Rituximab for primary chronic cold agglutinin disease: a prosepctive study of 37 courses of therapy in 27 patients” Blood 103(8) :2925-2928 (Apr. 15, 2004).Applicant
• Berger, “Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event” N. Engl J Med. 349(2):139-145 (Jul. 10, 2003).Applicant
• Bielekova et al., “Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand” Nat Med. 6(10):1167-1175 (Oct. 2000).Applicant
• Binstadt et al., “Rituximab therapy for multisystem autoimmune diseases in pediatric patients” Journal of Pediatrics 143:598-604 (Nov. 2003).Applicant
• Boletis, “An open study of B cell depletion in patients with proliferative lupus nephritis: Preliminary results” Journal of the American Society of Nephrology (Abstracts issue SA-PO378) 14:379A (Nov. 2003).Applicant
• Boomsma et al., “Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels” Arthritis and Rheumatism 43(9) :2025-2033 (Sep. 2000).Applicant
• Boomsma, M, “ANCA-associated vasculitis: occurrence, prediction, prevention, and outcome of relapses” Thesis University Groningen Chapter 1-11(ISBN 90-367-1451-6) :1-166 (2001).Applicant
• Booth et al., “Prospective Study of TNF Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis” J. Am. Soc. Nephrol. 15:717-721 (2004).Applicant
• Bouroncle et al., “Treatment of Wegener's granulomatosis with Imuran” Am. J. Med. 42:314-318 (1967).Applicant
• Calabrese, “Molecular differences in anticytokine therapies” Clinical and Experimental Rheumatology 21(2) :241-248 (2003).Applicant
• Cambridge et al., “B lymphocyte depletion in patients with rheumatoid arthritis: serial studies of immunological parameters” Arthritis Rheum 46(9) :S1350 (2002).Applicant
• Cambridge et al., “Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis” Arthritis and Rheumatism 48(8) :2146-2154 (Aug. 2003).Applicant
• Carter et al., “Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy” Proc. Natl. Acad. Sci. USA 89(10) :4285-4289 (May 1992).Applicant
• Cepok et al., “Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis” Brain 124(Pt 11) :2169-2176 (Nov. 2001).Applicant
• Chambers and Isenberg, “Anti-B cell therapy (rituximab) in the treatment of autoimmune disease” Lupus 14(3) :210-214 (2005).Applicant
• Chira and Sandborg, “Novel therapies in pediatric rheumatic diseases” Current Opinion in Pediatrics 15(6) :579-585 (2003).Applicant
• Clark et al., “Role of Bp35 Cell Surface Polypeptide in Human B-cell Activation” Proc. Natl. Acad. Sci. USA 82:1766-1770 (Mar. 1985).Applicant
• Cohen and Nagler, “Treatment of refractory autoimmune disease with ablative immunotherapy” Autoimmunity Reviews 3(2) :21-29 (Feb. 2004).Applicant
• Cohen and Nagler, “Treatment of refractory autoimmune diseases with lymphoablation and hematopoietic stem cell support” Israel Medical Association Journal 4(11 Suppl.) :865-867 (Nov. 1, 2002).Applicant
• Cohen et al., “Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support” Current Pharmaceutical Design 9(3) :279-288 (2003).Applicant
• Cohen Teravert et al., “Association Between Active Wegerner's Granulomatosis and Anticytoplasmic Antibodies” Arch. Intern. Med. 149:2461-2465 (Nov 1989).Applicant
• Cohen Tervaert et al., “Detection of Autoantibodies Against Myeloid Lysosomal Enzymes: A Useful Adjunct to Classification of Patients with Biopsy-Proven Necrotizing Arteritis” Am. J. Med. 91 :59-66 (Jul. 1991).Applicant
• Cohen Tervaert et al., “Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre” Lancet 336:709-711 (1990).Applicant
• CohenTervaert et al., “Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides” Sarcoidosis Vasc. Diffuse Lung Dis. 13:241-245 (1996).Applicant
• Coll et al., “Rituximab therapy for the type B syndrome of severe insulin resistance” N Engl J Med. 350(3) :310-311 (Jan. 15, 2004).Applicant
• Confavreux et al., “Relapses and progression of disability in multiple sclerosis” N Engl J Med. 343(20):1430-1438 (Nov. 16, 2000).Applicant
• Cooper et al., “The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura” Br. J. Haematol. 125:232-239 (2004).Applicant
• Cragg et al., “Complement-mediated-lysis by anti-CD20 mAb correlates with segration into lipid rafts” Blood 101(3) :1045-1052 (Feb. 1, 2003).Applicant
• Cragg et al., “The biology of CD20 and its potential as a target for mAb therapy” Curr. dir. Autoimmun. 8:140-174 (2005).Applicant
• Cross et al., “Preliminary Results from a Phase II trial of-Rituximab in MS” (Abstract), 8th Ann. Meeting of the Americas Committee, for Research and Treatment in Multiple Sclerosis pp. 20-21 (Oct 19, 2003).Applicant
• Crowley and Walters, “Determination of immunoglobulins in blood serum by high-performance affinity chromatography” J. Chromatogr. 266:157-162 (1983).Applicant
• Cupps et al., “Suppression of Human B Lymphocyte Function by Cyclophosphamide” J. Immunol. 128(6):2453-2457 (Jun. 1982).Applicant
• D'Arena et al., “Late and long-lasting response in an adult chronic idiopathic thrombocytopenic after extended course of rituximab” Leuk Lymphoma. 44(3) :561-562 (Mar. 2003).Applicant
• D'Cruz and Hughes, “The treatment of lupus nephritis” BMJ 330(7488) :377-378 (Feb. 2005).Applicant
• de Groot et al., “Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis” Arthritis and Rheumatism 39(12) :2052-2061 (Dec. 1996).Applicant
• De Vita et al., “Efficacy and Safety of Rituximab Treatment in Type II Mixed Cryoglobulinemia” Arthritis & Rheum. (ACR Concurrent Session Vaculitis: Novel Treatment and Pathogenesis Abstract #469) 46:S206 (Oct. 26, 2002).Applicant
• De Vita et al., “Efficacy of Selective B Cell Blockade in the Treatment of Rheumatoid Arthritis” Arthritis and Rheumatism 46(8) :2029-2033 (Aug. 2002).Applicant
• De'Oliviera et al., “Relationship Between Disease Activity and Anti-neutrophil Cytoplasmic Antibody Concentration in Long-Term Management of Systemic Vasculitis” Am J. Kidney Dis. 25(3) :380-389 (Mar. 1995).Applicant
• Demidem et al., “Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs” Cancer Biotherapy & Radiopharmaceuticals 12(3) :177-186 (1997).Applicant
• Doran et al., “Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study” Arthritis Rheum. 46(9) :2287-2293 (Sep. 2002).Applicant
• Dumont, “IDEC-131 IDEC/Eisai” Current Opinion in Investigational Drugs 3(5) :725-734 (May 1, 2002).Applicant
• Duna et al., “Wegener's granulomatosis” Rheum Dis Clin North Am. 21(4) :949-986 (Nov. 1995).Applicant
• Dupuy et al., “Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)” Arch Dermatol. 140(1) :91-96 (Jan. 2004).Applicant
• Edelbauer et al., “Rituximab in childhood systemic lups erythematosus refractory to conventional immunosuppression Case report” Pediatric Nephrology 20(6) :811-813 (2005).Applicant
• Edwards and Cambridge, “Sustained Improvement in Rheumatoid Arthritis Following a Protocol Designed to Deplete B Lymphocytes” Rheumatology 40:205-211 (2001).Applicant
• Edwards et al., “B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders” Biochemical Society Transactions 30 (part 4) :824-828 (2002).Applicant
• Edwards et al., “Efficacy and safety of Rituximab, a B-cell targeted chimeric monoclonal antibody: A randomized, placebo-controlled trial in patients with rheumatoid arthritis” Arthritis and Rheumatism (Abstract #446) 46(9) :S197 (2002).Applicant
• Edwards et al., “Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis” New England J. of Medicine 350(25) :2572-2581 (Jun. 17, 2004).Applicant
• Egg et al., “Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis” Mult Scler. 7(5) :285-289 (Oct. 2001).Applicant
• Einfeld et al., “Molecular Cloning of the Human B Cell CD20 Receptor Predicts a Hydrophobic Protein with Multiple Transmembrane Domains” EMBO Journal 7(3) :711-717 (1988).Applicant
• Eisenberg et al. “A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus” Arthritis Research and Therapy (Abstract #29) 5(Suppl 3) :S9-S10 (2003).Applicant
• Eisenberg R., “SLE—Rituximab in lupus” Arthritis Res Ther. 5(4) :157-159 (2003).Applicant
• Eisenberg, “Mechanisms of autoimmunity” Immunol. Res. 27(2-3) :203-217 (2003).Applicant
• Emery et al., “Efficacy and Safety of Rituximab at 2 Years Following a Single Treatment in Patients with Active Rheumatoid Arthritis” Arthritis and Rheumatism (Abstract #1762) S0(S9) :S659 (2004).Applicant
• Emery et al., “Sustained Efficacy at 48 Weeks after Single treatment Course of Rituximab in patients with Rheumatoid Arthritis” Arthritis Rheumatology (Abstract #1095) 48(9) :S439 (2003).Applicant
• Eriksson P., “Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab” J Intern Med. 257(6) :540-548 (Jun 2005).Applicant
• Eriksson, “Short-term outcome and safety in 5 patients with ANCA-positive vasculitis treadted with rituximab” Kidney and Blood Pressure Research (Abstract P87) 26:294 (2003).Applicant
• Esiri M., “Multiple sclerosis: a quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system” Neuropathol Appl Neurobiol 6(1) :9-21 (Jan. 1980).Applicant
• Falk et al., “Anti-Neutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase in Patients with Systemic Vasculitis and Idiopathic Necrotizing and Crescentic Glomerulonephritis” New England J. of Medicine 318(25) :1651-1657 (Jun 23, 1988).Applicant
• Falk et al., “Clinical Course of Anti-Neutrophil Cytoplasmic Autoantibody-associated Glomerulonephrities and Systemic Vasculitis” Annals of Internal Medicine 113(9) :656-663 (Nov. 1, 1990).Applicant
• Fauci et al., “The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations” Annals of Internal Medicine 89(5 Pt 1) :660-676 (Nov. 1978).Applicant
• Fauci et al., “Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years” Annals of Internal Medicine 98(1) :76-85 (Jan. 1983).Applicant
• Filippini et al., “Interferons in relapsing remitting multiple sclerosis: a systematic review” Lancet 361 (19357) :545-552 (Feb. 15, 2003).Applicant
• Foster et al., “Cytokine-receptor pairing: Accelerating discovery of cytokine function” Nature Reviews. Drug Discovery 3(2) :160-170 (Feb. 2004).Applicant
• Fra et al., “Reimission of refractory lupus nephritis with a protocol including rituximab” Lupus 12(10) :783-787 (2003).Applicant
• Gaskin et al., “Systemic vasculitis” Oxford textbook of clinical nephrology, Cameon et al., Oxford University Press vol. 1(4.5.3) :612-636 (1992).Applicant
• Genain et al., “Identification of autoantibodies associated wtih myelin damage in multiple sclerosis” Nat Med. 5(2) :170-175 (Feb. 1999).Applicant
• Gescuk, et al., “Novel Therapeutic Agents for Systemic Lupus Erythematosus” Current Opinion in Rheumatology 14:515-521 (2002).Applicant
• Glennie and van de Winkel, “Renaissance of cancer therapeutic antibodies” Drug Discov Today 8(11):503-510 (Jun. 1, 2003).Applicant
• Gong et al., “Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy” J. Immunol. 174:817-826 (2005).Applicant
• Gordon et al., “Relapses in patients with a systemic vasculitis” Q J. Med 86(12) :779-789 (Dec. 1993).Applicant
• Gordon et al., “Zevalin™ radioimmunotherapy is associated with a low incidence of human-anti mouse antibody (HAMA) and human anti-RituxanR antibody (HACA) response”. Blood (Abstract #4632) 98(11 Part 2) :228b (2001).Applicant
• Gorman et al., “B cell depletion in autoimmune disease” Arthritis Research and Therapy 5(Supplement 4) :S17-S21 (2003).Applicant
• Gorman et al., “Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?” Lupus 13(5) :312-316 (2004).Applicant
• Goronzy and Weyand, “B cells as a therapeutic target in autoimmune disease” Arthritis Research and Therapy 5(3) :131-135 (Mar. 19, 2003).Applicant
• Gottenberg et al., “Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases” Annals of the Rheumatic Diseases 64(6) :913-920 (2005).Applicant
• Guillevin et al., “Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss Syndrome: Indications for the classification of vasculitides of the polyarteritis nodose group” Br. J. Rheumatology 35(10) :958-964 (1996).Applicant
• Guillevin et al., “Churg-Strauss Syndrome: Clinical Study and Long-Term Follow-Up of 96 Patients” Medicine 78(1) :26-37 (Jan. 1999).Applicant
• Guillevin et al., “Microscopic Polyangiitis” Arthritis and Rheumatism 42(3) :421-430 (Mar. 1999).Applicant
• Hainsworth, “Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma” J Clin Oncol. 20(20) :4261-4267 (Oct. 15, 2002).Applicant
• Hainsworth, “Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network” J Clin Oncol. 21(9) :1746-1751 (May 1, 2003).Applicant
• Hamaguchi et al., “The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice” J. Immunol. 174:4389-4399 (2005).Applicant
• Hasak Janet, “Statement of Janet E. Hasak for” pp. 1-2 (Oct., 8, 2004).Applicant
• Haubitz et al., “Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis” Nephrol. Dial. Transplant 13:2074-2076 (1998).Applicant
• Hellmich and Gross, “The annual European Congress of Rheumatology: Recent advances in the treartment of rheumatic diseases” Expert Opinion on Investigational Drug 12(10) :1713-1719 (2003).Applicant
• Hoffman et al., “Wegener Granulomatosis: An Analysis of 158 Patients” Annals of Internal Medicine 116:488-498 (Mar. 15, 1992).Applicant
• Hong e tal., “Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20” Journal of Immunological Methods 294:189-197 (2004).Applicant
• Houssiau, “Management of refractory systemic rheumatic diseases” Acta Clinica Belgica 58(5) :314-317 (2003).Applicant
• Idusogie et al., “Engineered antibodies with increased activity to recruit complement” J. Immunol. 166(4) :2571-2575 (2001).Applicant
• Isenberg and Leckie, “Biological treatments for systemic lupus erythematosus” Scandinavian Journal of Rheumatology 31(4) :187-191 (2002).Applicant
• Izquierdo, “Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients” Acta Neurol Scand. 105(3) :158-163 (Mar. 2002).Applicant
• Izzedine et al., “Lymphopenia in Wegener s Granulomatosis” Nephron 92:466-471 (2002).Applicant
• Jayne and Rasmussen, “Treatment of Antineutrophil Cytoplasm Autoantibody-Associated Systemic Vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group” Mayo Clin. Proc. 72:737-747 (Aug. 1997).Applicant
• Jayne et al., “A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies” New England J. of Medicine 349:36-44 (Jul. 3, 2003).Applicant
• Jayne et al., “ANCA and predicting relapse in systemic vasculitis” QJM 88(2) :127-133 (Feb. 1995).Applicant
• Jayne et al., “B-cell depletion with rituximab for refractory vasculitis” Kidney and Blood Pressure Research (Abstract P88) 26:294-295 (2003).Applicant
• Jayne, “Current attitudes to the therapy of vasculitis” Kidney and Blood Pressure Research 26(4) :231-239 (2003).Applicant
• Jayne, “Evidence-based treatment of systemic vasculitis” Rheumatology 39:585-595 (2000).Applicant
• Jennette and Falk, “Small-vessel vasculitis” New England J. of Medicine 337:1512-1523 (Nov. 20, 1997).Applicant
• Jennette et al., “Nomenclature of Systemic Vasculitides” Arthritis and Rheumatism 37(2) :187-192 (Feb. 1994).Applicant
• Jilani Iman et al., “Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia” Blood 102(10) :3514-3520 (Nov. 15, 2003).Applicant
• Jinno Yoshio et al., “Local Expansion of Plasma-Lineage Cells Without Formation of Germinal Centers Characterizes Ulcerative Colitis” Digestive Disease Week Abstract and Itinerary (Abstract #M1164) (2003).Applicant
• Jordan, “Intravenous Gamma-Globulin Therapy in systemic Lupus Erythematosus and Immune Complex Disease” Clin. Immunol. Immunopathol. 53:S164-S169 (1989).Applicant
• Kalled et al., “BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders” Expert Opinion on Therapeutic Targets 7(1) :115-123 (2003).Applicant
• Kamesh et al., “ANCA-Positive Vasculitis” J. Am. Soc. Nephrol. 13:1953-1960 (2002).Applicant
• Kaminski, M. et al., “Development of HAMA after Bexxar™ therapy does not preclude treatment with rituximab” Blood (Abstract #3172) 96(11 Part 1) :734a (2000).Applicant
• Kazkaz and Isenberg, “Anti B cell Therapy (rituximab) in the treatment of auroimmune diseases” Current Opinion in Pharmacology 4:398-402 (2004).Applicant
• Keogh et al., “Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis” Arthritis Rheum. 52(1) :262-268 (Jan. 2005).Applicant
• Keogh et al., “Rituximab—A Potential Mechanistic-Based Therapy for Treatment of Refractory ANCA-Associated Vasculitis” Kidney Blood Pressure Research (Abstract #O32) 26:293 (2003).Applicant
• Keogh et al., “Rituximab for Refratory Wegener's Granulomatosis: Report of A Prospective, Open-Label Pilot Trial” AJRCCM Articles in Press pp. keogh-0-33 (Oct 13, 2005).Applicant
• Keogh et al., “Rituximab for Remission Induction in Severe ANCA-Associated Vasculities. A Report of a Prospective Open-Label Pilot in 10 Patients” American College of Rheumatology, Session title: Vasculitis (Abstract 605) (Oct. 18, 2004).Applicant
• Klemmer et al., “Treatment of antibody mediated autoimmune disorders with a Anti-CD20 monoclonal antibody Rituximab” Arthritis and Rheumatism (Abstract #1623) 48(Suppl 9) :S624 (2003).Applicant
• Kneitz et al., “Effective B cell depletion with rituximab in the treatment of autoimmune diseases” Immunobiology 206:519-527 (2002).Applicant
• Koper, N. et al., “Quantitation of IgG and IgM human anti-mouse antibodies (HAMA) interference in CA 125 measurements using affinity chromatography” Clin. Chem. Lab. Med 36(1) :23-28 (1998).Applicant
• Kremenchutzky et al., “The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation” Brain 122 (Pt 10) :1941-1949 (Oct. 1999).Applicant
• Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)” Neurology 33(11) :1444-1452 (Nov. 1983).Applicant
• Lake and Dionne, “Future Strategies in Immunotherapy” Burger's Medicinal Chemistry and Drug Discovery, Abraham, 6th edition, Hoboken:John Wiley & Sons, Inc., Chapter 6, vol. 5:223-247 (2003).Applicant
• Langford, “Treatment of ANCA-Associated Vasculitis” New England J. of Medicine 349:3-4 (Jul. 3, 2003).Applicant
• Layios et al., “Remission of severe cold agglutinin disease after Rituximab therapy” Leukemia 15(1) :187-188 (Jan. 2001).Applicant
• 'Leandro et al., “An open study of B lymphocyte depletion in systemic lupus erythematosus” Arthritis and Rheumatism 46(10) :2673-2677 (Oct 2002).Applicant
• Leandro et al., “B cell repopulation occurs mainly from naive B cells in patients with rheumatoid arthritis and systemic lupus erythematosus treated with rituximab” Arthritis and Rheumatism (Abstract #1160) 48(Suppl 9) :S464 (Oct. 27, 2003).Applicant
• Leandro et al., “B Lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response” Arthritis and Rheumatism (#1905) 44(9) :S370 (2001).Applicant
• Leandro et al., “Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion” Annals of the Rheumatic Diseases 61(10) :883-888 (2002).Applicant
• Leandro et al., “Treatment of refractory lupus nephritis with B lymphocyte depletion” Arthritis and Rheumatism (Abstract #924) 48 (Supplement 9) :S378 (2003).Applicant
• Lee and Kueck, “Rituxan in the Treatment of Cold Agglutinin Disease” Blood 92:3490-3491 (1998).Applicant
• The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI, “TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study” Neurology 53(3) :457-465 (Aug. 11, 1999).Applicant
• Leon et al., “Interference by rheumatoid factor activity in the detection of antiavian antibodies in pigeon breeders disease” Clin. Exp. Med. (Abstract) 2(2) :59-67 (Jul. 2002).Applicant
• Levine and Pestronk, “IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab” Neurology 52(8) :1701-1704 (May 12, 1999).Applicant
• Levine, “A Pilot Study of Rituximab Therapy for Refractory Dermatomyositis” Arthritis Rheum. (Abstract #1299) 46 (Suppl. 9) :S488-S489 (2002).Applicant
• Lhote and Guillevin, “Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment” Rheumatic Disease Clinics of North America 21(4) :911-947 (Nov. 1995).Applicant
• Liang and Tedder, “CD20” CD20 Wiley Encyclopedia of Molecular Medicine pp. 562-564 (Jan. 15, 2002).Applicant
• Linnik et al., “Workshop report on some new ideas about the treatment of systemic lupus erythematosus” Lupus 11(12) :793-796 (2002).Applicant
• Lockshin and Sammaritano, “Lupus pregnancy” Autoimmunity 36(1) :33-40 (2003).Applicant
• Looney et al., “B-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalating trial of rituximab” Arthritis and Rheumatism 50(8) :2580-2589 (Aug. 2004).Applicant
• Looney et al., “Treatment of SLE with anti-CD20 monoclonal antibody” Curr. Dir. Autoimmun. 8:193-205 (2005).Applicant
• Looney, “B cell-targeted therapy in diseases other than rheumatoid arthritis” J. Rheumatology 32(Suppl. 73) :25-28 (2005).Applicant
• Looney, “B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis” Rheumatology 44(Suppl. 2) :ii13-ii17 (2005).Applicant
• Looney, “Treating human autoimmune disease by depleting B cells” Annals of the Rheumatic Diseases 61:863-866 (2002).Applicant
• Lucchinetti et al., “Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination” Ann Neurol. 47(6) :707-717 (Jun. 2000).Applicant
• MacDermott et al., “Alterations of IgM, IgG, and IgA synthesis and secretion by peripheral blood and intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease” Gastroenterology 84:844-852 (Nov. 1981).Applicant
• Maeda, T. et al., “Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody” Intl. J. Hematology 74(1):70-75 (2001).Applicant
• Maloney et al., “The Anti-Tumor Effect of Monoclonal Anti-CD20 Antibody (mAb) Therapy Includes Direct Anti-Proliferative Activity and Induction of Apoptosis in CD20 Positive Non-Hodgkin's Lymphoma (NHL) Cell Lines” Blood (Abstract #2535) 88(10) :637a (1996).Applicant
• Manches et al., “In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas” Blood 101(3) :949-954 (Feb. 1, 2003).Applicant
• Martin and Chan, “Pathogenic roles of B cells in human autoimmunity; insights from the clinic” Immunity 20(5) :517-527 (may 2004).Applicant
• Mata et al., “Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a” Mult Scler. 5(6) :379-388 (Dec. 1999).Applicant
• Matthews, R., “Medical Heretics” New Scientist 170(2285):34-37 (Apr. 7, 2001).Applicant
• McDonald et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis” Ann Neurol. 50(1) :121-127 (Jul. 2001).Applicant
• McKeever et al., “A Toxicity Evaluation of Humanized-Anti-CD20 Antibody PRO70769” Society of Toxicology Annual Meeting, Baltimore, Maryland (Poster #75) 78(S-1):15 (Mar. 22, 2004).Applicant
• Mehta et al., “Exacerbation of lupus while receiving rituximab for chronic refractory thrombocytopenia” Blood (Abstract #3862) 98(11) :61b-62b (Nov. 16, 2001).Applicant
• Mintzer David Michael, “Combined Autoimmune Thrombocytopenia Blood Neutropenia: Treatment with Rituximab” Blood (Abstract #3635) 100(11) (Nov. 16, 2002).Applicant
• Mire-Sluis, A. et al., “Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products” J. Immunol. Methods 289:1-16 (2004).Applicant
• Nachman et al., “Treatment Response and Relapse in Antineutrophil Cytoplasmic Autoantibody-Associated Microscopic Polyangiitis and Glomerulonephritis1 2” J. Am. Soc. Nephrol. 7:33-39 (1996).Applicant
• Neuwelt, “The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus” Therapeutic Apheresis and Dialysis 7(2) :173-182 (Apr. 2003).Applicant
• Niles et al., “The Syndrome of Lung Hemorrhage and Nephritis Is Usually an ANCA-Associated Condition” Arch. Intern. Med. 156:440-445 (Feb. 1996).Applicant
• Nobile-Orazio, “IgM paraproteinaemic neuropathies” Curr. Opin. Neurol. 17(5) :599-605 (Oct. 17, 2004).Applicant
• Noonan et al., “Prevalence estimates for MS in the United States and evidence of an increasing trend for woman” Neurology 58(1) :136-138 (Jan. 8, 2002).Applicant
• Norton et al., “Combined corticosteroid and azathioprine therapy in 2 patients with Wegner's granulomatosis” Archives of Internal Medicine 121(6) :554-560 (Jun. 1968).Applicant
• Nowack et al., “Mycophenolate Mofetil for Maintenance Therapy of Wegner s Granulomatosis and Microscopic Polyangiitis: A Pilot Study in 11 Patients with Renal Involvement” J. Am. Soc. Nephrol. 10:1965-1971 (1999).Applicant
• O'Connor, “Key issues in the diagnosis and treatment of multiple sclerosis. An overview” Neurology 59(6 Supp 3) :S1-S33 (Sep. 24, 2002).Applicant
• Oelke, “American College of Rheumatology—65th Annual Meeting” IDrugs 5(1) :30-31 (2002).Applicant
• Onuma et al., “Autoimmunity in ulcerative colitis (UC): a predominant colonic mucosal B cell response against human tropomyosin isoform 5” Clin Exp. Immunol. 121:466-471 (2000).Applicant
• Park and Smolen, “Monoclonal antibody therapy” Advances in Protein Chemistry 56:369-421 (2001).Applicant
• Patel et al., “Graft-versus-Kaposi's Sarcoma effect and reversal of Lupus Anticoagulant Syndrome and Thalassemia Intermedia after non-myeloablative allogeneic stem cell transplant” Blood (Abstract 5256) 98(11) :370b (Nov. 16, 2001).Applicant
• Pavelka et al., “Improvement in patient-reported outcomes with rituximab in patients with rheumatoid arthritis” Annals of the Rheumatic Diseases (Abstract FRI0135) 63(S1) :289-290 (2004).Applicant
• Penichet and Morrison, “Antibody Engineering” Wiley Encyclopedia of Molecular Medicine (Section: Chimeris, Humanized and Human Antibodies) pp. 214-216 (2002).Applicant
• Perrotta and Abuel, “Response of Chronic Relapsing ITP of 10 Years Duration to Rituximab” Blood (Abstract #3360) 92(10 Suppl. 1 Part 1-2) :88b (1998).Applicant
• Perrotta et al., “Rituxan in the treatment of chronic idiopathic thrombocytopenia purpura (ITP)” Blood (Abstract #49) 94:14a (1999).Applicant
• Perrotta, “Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus” British Journal of Haematology 116(2) :465-467 (Feb. 2002).Applicant
• Pestronk et al., “Treatment of IgM antibody associated polyneuropathies using rituximab” J. Neurol Neurosurg Psychiatry 74(4) :485-489 (Apr. 2003).Applicant
• Pettersson et al., “Incidence and outcome of pauci-immune necrotizing and crescentic glomerulonephritis in adults” Clinical Nephrology 43(3) :141-149 (1995).Applicant
• Podolsky, D., “Inflammatory Bowel Disease” New England J. of Medicine 347(6) :417-429 (Aug. 8, 2002).Applicant
• Popa et al., “Differential B- and T-cell activation in Wegener's granulomatosis” J. Allergy Clin. Immunol. 103 :885-894 (May 1999).Applicant
• Pranzatelli et al., “CSF B-Cell Over-Expansion in Paraneoplastic Opsoclonus-Myoclonus: Effect of Rituximab, an Anti-B-Cell Monoclonal Antibody” Neurology (Abstract #P05.128) 60(5(suppl 1)) :A395 (Mar. 2003).Applicant
• Press et al., “Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of Human B Cell Lymphomas” Blood 69(2) :584-591 (Feb. 1987).Applicant
• Prineas and Wright, “Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis” Laboratory Investigation 38(4) :409-421 (Apr. 1978).Applicant
• Protheroe et al., “Remission of Inflammatory Arthropathy in Association with Anti-CD20 Therapy for Non-Hodgkin's Lymphoma” Rheumatology 38(11) :1150-1152 (Nov. 1999).Applicant
• Quartier et al., “Treatment of childhood autoimmune haemolytic anaemia with rituximab” Lancet 358:1511-1513 (Nov. 3, 2001).Applicant
• Radis et al., “Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis” Arthritis and Rheumatism 38 (8) :1120-1127 (Aug. 1995).Applicant
• Rahman, “Cytokines in systemic lupus erythematosus, London, UK” Arthritis Research and Therapy 5 (4) :160-164 (2003).Applicant
• Raj et al., “Successful Treatment of Refractory Autoimmune Hemolytic Anemia With Monthly Rituximab Following Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease” J. Pediatr. Hematol. Oncol. 26(5):312-314 (May 2004).Applicant
• Rastetter et al., “Rituximab: expanding role in therapy for lymphomas and autoimmune diseases” Annual Review of Medicine 55:477-503 (2004).Applicant
• Ratanatharathorn et al., “Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease” Ann Intern Med. 133(4) :275-279 (Aug. 15, 2000).Applicant
• Reff et al., “Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20” Blood 83(2) :435-445 (1994).Applicant
• Reindl et al., “Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study” Brain 122 (Pt 11) :2047-2056 (Nov. 1999).Applicant
• Reinhold-Keller et al., “An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients” Arthritis and Rheumatism 43(5) :1021-1032 (May 2000).Applicant
• Renaud et al., “Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies” Muscle Nerve 27(5) :611-615 (May 2003).Applicant
• Robak, “Monoclonal antibodies in the treatment of autoimmune cytopenias” European Journal of Haematology 72:79-88 (2004).Applicant
• Rojas-Garcia et al., “Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximab” Neurology 61(2 of 2) :1814-1816 (Dec. 2003).Applicant
• Rudick et al., “Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains” Mult Scler. 1(3) :150-155 (Nov. 1995).Applicant
• Russell et al., “Detection of Anti-Neutrophil Cytoplasmic Antibodies under Actual Clinical Testing Conditions” Clinical Immunology 103(2) :196-203 (2002).Applicant
• Sadatipour, “Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis” Ann Neurol. 44(6) :980-983 (Dec. 1998).Applicant
• Saigal et al., “Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab” Journal of the American Academy of Dermatology 49(Supplement 5 ) :S283-S285 (Nov. 2003).Applicant
• Saito et al., “Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement” Lupus 12:798-800 (2003).Applicant
• Saleh et al., “A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refratctory immune thrombocytopenia” Semin Oncol. 27(6 Supp 12) :99-103 (Dec 2000).Applicant
• Sanders et al., “Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies” New England J. of Medicine 349(21) :2072-2073 (Nov. 20, 2003).Applicant
• Sarwal et al., “Molecular Heterogeneity in Acute Renal Allograft Rejection Identified by DNA Microarray Profiling” New England J. of Medicine 349(2) :125-138 (Jul. 10, 2003).Applicant
• Savage et al., “Primary systemic vasculitis” Lancet 349:553-558 (Feb. 22, 1997).Applicant
• Sfikakis et al., “Remission of Proliferative Lupus Nephritis Following B Cell Depletion Therapy Is Preceded by Down-Regulation of the T Cell Costimulatory Molecule CD40 Ligand” Arthritis and Rheumatism 52(2) :501-513 (Feb. 2005).Applicant
• Sfikakis PP et al., “Clinical Responses Correlate with Deactivation of T Cells Following Therapeutic B Cell Depletion in Patients With Lupus Nephritis” Cutting edge in rheumatology 3 (EULAR Berlin, 1 page) (Jun. 11, 2004).Applicant
• Shan, D. et al., “Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells” Cancer Immunol. Immunother. 48(12) :673-683 (2000).Applicant
• Shanahan et al., “Upcoming biologic agents for the treatment rheumatic diseases” Current Opinion in Rheumatology 15(3) :226-236 (May 2003).Applicant
• Shaw et al., “B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience” Ann Rheum Dis. 62(Suppl. 2) :ii55-ii59 (Nov. 2003).Applicant
• Siden A., “Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS” J. Neurol. 221(1) :39-51 (Jul. 11, 1979).Applicant
• Silverman and Weisman, “Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy” Arthritis and Rheumatism 48(6) :1484-1492 (Jun. 2003).Applicant
• Silverman, “Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic” Arthritis and Rheumatism 52(2) :371-377 (Feb. 2005).Applicant
• Smith and Jayne, “A Prospective, Open Label Trial of B-cell Depletion with Rituximab in Refractory Systemic Vasculitis” Journal of the American Society of Nephrology (11th International Vasculitis and ANCA workshop) 14(Poster # SU-P0998) :755A (2003).Applicant
• Solsky and Wallace, “New therapies in systemic lupus erythematosus” Best Practice and Research Clinical Rheumatology 16(2) :293-312 (2002).Applicant
• Somer et al., “Improvement in Sjogren's syndrome following therapy with rituximab for margianl zone lymphoma” Arthritis and Rheumatism 49(3) :394-398 (Jun. 15, 2003).Applicant
• Song and McCutcheon, “Strategies, Challenges and Design of Neutralizing Antibody Assays for Biotherapeutics: Development of a Cell-based Rituximab-RA NAb Assay” (Slides presnted at Immunogenicity for Biotherapeutics Conference, San Francisco, CA, USA,) pp. 1-23 (May 23-25, 2005).Applicant
• Song, A., “Strategies, Challenges and Design of Neutralizing Antibody Assays for Biotherapeutics: Development of a Cell-based Rituximab-RA NAb Assay” (Abstract with Slides presented at Biological Assay Development & Validation Conference, Reston, VA, USA,) pp. 1-19 (Apr. 25-27, 2005).Applicant
• Specks et al., “Response of Wegener's Granulomatosis to anti-CD20 Chimeric Monoclonal Antibody Therapy” Arthritis and Rheumatism 44(12) :2836-2840 (Dec. 2001).Applicant
• Stahl et al., “Rituximab in RA: Efficacy and safety from a randomised, controlled trial” Ann. Rheum. Dis. (OP0004) 62(Suppl. 1) (2003).Applicant
• Stahl, D. et al., “Serum affinity chromatography for the detection of IgG alloantibodies in a patient with high-titer IgM cold agglutinins” Vox Sanguinis 74(4) :253-255 (1998).Applicant
• Stasi et al., “Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura” Blood 98(4) :952-957 (Aug. 15, 2001).Applicant
• Stegeman et al., “Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis” Annals of Internal Medicine 120(1) :12-17 (Jan. 1, 1994).Applicant
• Stegeman et al., “Trimethoprim-Sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's Granulomatosis” New England J. of Medicine 335(1) :16-20 (Jul. 4, 1996).Applicant
• Stillwell et al., “Cyclophosphamide-induced bladder toxicity in Wegner's granulomatosis” Arthritis and Rheumatism 31(4) :465-470 (Apr. 1988).Applicant
• Stockinger et al., “Monoclonal Antibodies to Human Cell Surface Antigens” Current Protocols in Immunology (Appendix 4A), Coligan et al., John Wiley & Sons, Inc. pp. A.4A.1-A4A.49 (Feb. 2003).Applicant
• Stockwin and Holmes, “Antibodies as therapeutic agents: Vive la renaissance” Expert Opinion on Biological Therapy 3(7) :1133-1152 (2003).Applicant
• Stone et al., “A Disease-Specific Activity Index for Wegener's Granulomatosis” Arthritis and Rheumatism 44(14) :912-920 (Apr. 2001).Applicant
• Stone et al., “Etantercept Combined With Conventional Treatment in Wegner's Granulomatosis” Arthritis and Rheumatism 44(5) :1149-1154 (May 2001).Applicant
• Stone et al., “Test Characteristics of Immunofluorescence and ELISA Tests in 856 Consecutive Patients with Possible ANCA Associated Conditions” Arthritis Care and Research 13:424-434 (2000).Applicant
• Strand et al., “Outcome Measures To Be Used in Clinical Trials in Systemic Lupus Erythematosus” J. Rheumatology 26:490-497 (1999).Applicant
• Su and Madaio, “Recent Advances in the Pathogenesis of Lupus Nephritis: Autoantibodies and B Cells” Seminars in Nephrology 23(6) :564-568 (Nov. 2003).Applicant
• Szczepanski et al., “Safety Data From 48 weeks Follow-Up of a Randomised Controlled trial of Rituximab in Patients with Rheumatoid Arthritis” Arthritis Rheumatology (Abstract #204) 48(9) :S121 (2003).Applicant
• Tahir et al., “Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lups erythematosus in a patient with antibodies against rituximab” Rheumatology 44(4) :561-562 (2005).Applicant
• Taylor, “Antibody therapy for rheumatoid-arthritis” Current Opinion in Pharmacology 3(3) :323-328 (2003).Applicant
• Tedder et al., “The B Cell Surface Molecule B1 is Functionally Linked with B Cell Activation and Differentiation” The Journal of Immunology 135 (2) :973-979 (Aug. 1985).Applicant
• Tedder et al., “The CD20 Surface Molecule of B Lymphocytes Functions as a Calcium Channel” J. Cell. Biochem. (Abstract #M 023) 14D:195 (1990).Applicant
• ten Cate et al., “Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus” Rheumatology 43(2) :244-245 (Feb. 2004).Applicant
• Tokunaga et al., “Down-regulation ot CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab” Rheumatology 44(2) :176-182 (2005).Applicant
• Tomietto et al., “B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus” Thromb. Haemost. 92:1150-1153 (2004).Applicant
• Treon et al., “The Use of Rituximab in the Treatment of Malignant and Nonmalignant Plasma Cell Disorders” Seminars in Oncology 27(6, Suppl. 12) :79-85 (Dec. 2000).Applicant
• Tuscano et al., “B lymphocytes contribute to autoimmune disease pathogenesis: Current trends and clinical implications” Autoimmunity Reviews 2(2) :101-108 (2003).Applicant
• Tuscano et al., “Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab” Annual Scientific Meeting of the American College of Rheumatology (Presentation #LB11, Poster #444), New Orleans, LA (Oct. 24-29, 2002).Applicant
• Uchida et al., “The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy” Journal of Experimental Medicine 199(12) :1659-1669 (Jun. 21, 2004).Applicant
• Valente, “Chapter 68—Vasculitis and related disorders” Textbook of Rheumatology, Saunders, 5th edition, Philadelphia pp. 1079-1101 (1997).Applicant
• Valentine et al., “Anti-CD20 monoclonal antibody (rituximab, RTX) therapy in a hemodialysis (HD) patient (Pt) with severe systemic lupus erythematosis (SLE)” Journal of the American Society of Nephrology (Abstract #PUB064) 13:683A (Sep. 2002).Applicant
• Valentine et al., “B3.9 Structure and function of the B-cell specific 35-37κDa CD20 protein” Leukocyte Typing III (B-cell antigens—papers), McMichael, Ed., Oxford University Press pp. 440-443 (1987).Applicant
• Valentine et al., “Phosphorylation of the CD20 Phosphoprotein in Resting B Lymphocytes” J. Bio. Chem. 264(19) :11282-11287 (1989).Applicant
• Villar et al., “Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis” Ann Neurol. 53(2) :222-226 (Feb. 2003).Applicant
• Virgolini and Marzocchi, “Rituximab in autoimmune diseases” Biomedicine & Pharmacotherapy 58:299-309 (2004).Applicant
• Vugmeyster et al., “Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis” J. Immunotherapy 28(3) :212-219 (May/Jun. 2005).Applicant
• Wallace, “Management of lupus erythematosus: recent insights” Current Opinion in Rheumatology 14(3) :212-219 (May 2002).Applicant
• Wei et al., “Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies” J. Immunol. Methods 293(1-2) :115-126 (Oct. 2004).Applicant
• Weide et al., “Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy” Lupus 12:779-782 (2003).Applicant
• Weinshenker et al., “The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability” Brain 112:133-146 (Feb. 1989).Applicant
• Weinstein et al., “B-cell biology” Rheumatic Disease Clinics of North America 30(1) :159-174 (2004).Applicant
• Weyand and Goronzy, “Ectopic Germinal Center Formation in Rheumatoid Synovitis” Ann. N.Y. Acad. Sci. 987:140-149 (2003).Applicant
• Wiestner et al., “Rituximab in the treatment of acquired factor VIII inhibitors” Blood 100 (9) :3426-3428 (Nov. 1, 2002).Applicant
• Wiik, “Delineation of a standard procedure for indirect immunofluorescence detection of ANCA” APMIS 97(Suppl. 6) :12-13 (1989).Applicant
• Wingerchuk et al., “Multiple sclerosis: current pathophysiological concepts” Laboratory Investigation 81(3) :263-281 (Mar. 2001).Applicant
• Wolinsky, “The diagnosis of primary progressive multiple sclerosis” J Neurol Sci. 206(2) :145-152 (Feb. 15, 2003).Applicant
• Wylam et al., “Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report” J Pediatr. 143(5) :674-677 (Nov. 2003).Applicant
• Xiao et al., “Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice” J. Clin. Invest. 110(7) :955-963 (Oct. 2002).Applicant
• Zaja et al., “B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia” Haematologica 87(2) :189-195 (Feb. 2002).Applicant
• Zaja et al., “Efficacy and safety of rituximab in type II mixed cryoglobulinemia” Blood 101(10) :3827-3834 (May 15, 2003).Applicant
• Zaja et al., “Rituximab for myasthenia gravis developing after bone marrow transplant” Neurology 55(7) :1062-1063 (Oct. 10, 2000).Applicant
• Zaja et al., “Rituximab for the treatment of type II mixed cryoglobulinemia” Haematologica 84(12) :1157-1158 (Dec. 1999).Applicant
• Zaja et al., “Rituximab in a case of cold agglutinin disease” Br J Haematol. 115:232-233 (Oct. 2001).Applicant
• Zaja et al., “The B-cell compartment as the selective target for the treatment of immune thrombocytopenias” Haematologica 88(5) :538-546 (May 2003).Applicant
• Zaya, F. et al., “Rituximab for the treatment of autoimmune disease” Blood (Abstract #3770) 98(11 Part 2) :41b (2001).Applicant
• Zecca et al., “Rituximab for the treatment of refractory autoimmune hemolytic anemia in children” Blood 101(10) :3857-3861 (May 15, 2003).Applicant
• Zeman et al., “Cerebrospinal fluid cytologic findings in multiple sclerosis. A comparison between patient subgroups” Acta Cytol. 45(1) :51-59 (Jan.-Feb. 2001).Applicant
• Higashida et al., “Treatment of DMARD-Refractory Rheumatoid Arthritis With Rituximab” Annual Scientific Meeting of the American College of Rheumatology (Abstract #LB11), New Orleans, LA (Oct. 2002).Applicant
• Stone and Specks, “Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-associated Vasculitis. Clinical Trial Research Summary of the 2002-2003 Immune Tolerance Network” American Society of Nephrology (11th International Vasculitis and ANCA workshop)(Poster 88).Applicant